1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Singulair (Asthma) - Forecast and Market Analysis to 2023

Singulair (Asthma) - Forecast and Market Analysis to 2023


GlobalData has released its new PharmaPoint Drug Evaluation report, “Singulair (Asthma) - Forecast and Market Analysis to 2023”. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Singulair, developed by Merck, is a CysLT1 receptor inhibitor, blocking the physiologic actions of leukotriene D4 (LTD4). LTD4 belongs to the family of Cys-LTs, which are mediators released from a variety of cells, including mast cells and eosinophils, and which bind to the family of CysLT receptors. Several studies have determined that there are higher concentrations of Cys-LTs in the airways and urine of asthmatics compared with non-asthmatic individuals. The production of CysLTs is increased in asthmatics, particularly during the early phase of bronchoconstriction that follows allergen challenge. Cys-LT signaling results in airway edema, smooth muscle contraction, and aberrant immune cell activity.


- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Singulair including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Singulair for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Asthma
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Singulair performance
- Obtain sales forecast for Singulair from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table Of Contents

Singulair (Asthma) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Prognosis 15
3.1.4 Quality of Life 15
3.2 Symptoms 15
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Diagnosis 17
4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs 18
4.1.3 Clinical Practice 20
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 27
6 Singulair (montelukast) 31
6.1 Overview 31
6.2 Efficacy 33
6.3 Safety 34
6.4 SWOT Analysis 35
6.5 Forecast 35
7 Appendix 37
7.1 Bibliography 37
7.2 Abbreviations 41
7.3 Methodology 44
7.4 Forecasting Methodology 44
7.4.1 Diagnosed Asthma Patients 44
7.4.2 Percent Drug-Treated Patients 45
7.4.3 General Pricing Assumptions 45
7.4.4 Individual Drug Assumptions 46
7.4.5 Generic Erosion 46
7.5 Physicians and Specialists Included in This Study 47
7.6 About the Authors 50
7.6.1 Author 50
7.6.2 Author/Reviewer 50
7.6.3 Reviewer 51
7.6.4 Global Head of Healthcare 52
7.7 About GlobalData 53
7.8 Disclaimer 53

1.1 List of Tables

Table 1: Symptoms of Asthma 16
Table 2: Treatment Guidelines for Asthma by Country 18
Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013 19
Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency 22
Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age 24
Table 6: Leading Treatments for Asthma, 2014 30
Table 7: Product Profile - Singulair 33
Table 8: Efficacy - Singulair+Pulmicort Versus Double-Dose of Pulmicort 34
Table 9: Safety of Singulair+Pulmicort Compared With a Double Dose of Pulmicort 34
Table 10: Singulair SWOT Analysis, 2014 35
Table 11: Global Sales Forecast ($) for Singulair, 2013-2023 36
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 49

1.2 List of Figures

Figure 1:Stepwise Disease Management Approach for Asthma in Adults 21
Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Pulmonary Arterial Hypertension (PAH) Therapeutics - Pharmaceuticals

Global Pulmonary Arterial Hypertension (PAH) Therapeutics - Pharmaceuticals

  • $ 4500
  • Industry report
  • January 2017
  • by Global Industry Analysts

This report analyzes the worldwide markets for Pulmonary Arterial Hypertension (PAH) Therapeutics in US$ Million. The Global market is analyzed by the following Drug Class and Brands: Endothelin Recepto ...

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

  • $ 2500
  • Industry report
  • December 2016
  • by Infiniti Research Limited

About Human Respiratory Syncytial Virus Drugs Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages ...

Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016

Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • November 2016
  • by GlobalData

Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016" provides an overview of ...

Tygacil -drug Insights, 2017

January 2017 $ 1000


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.